Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer
- 17 April 2007
- journal article
- clinical trial
- Published by Wiley in The Prostate
- Vol. 67 (9) , 933-942
Abstract
BACKGROUND: The purpose of this study was to determine the safety and immune responses of pre‐operative personalized peptide vaccine for patients with localized prostate cancer.METHOD: Ten human leukocyte antigen (HLA)‐A24+ patients with localized prostate cancer received weekly personalized peptide vaccine for six times with positive peptides (up to four kinds of peptides) from 16 kinds of vaccine candidates, followed by a retropubic radical prostatectomy (RRP). Eight patients with localized prostate cancer receiving RRP served as the control group. The serum prostate‐specific antigen (PSA) level, and peptide‐specific cytotoxic T lymphocyte (CTL) precursor analysis by interferon‐γ production, and peptide‐reactive immunoglobulin G (IgG) using an enzyme‐linked immunosorbent assay were monitored during the treatment. Distributions of CD45RO+ cells, CD8+ T cells, and CD20+ B cells in tissue microarray samples were studied using an immunohistochemical technique.RESULT: The peptide vaccination was safe and well tolerated with no major adverse effects. Increased CTL response and the anti‐peptide IgG titer were observed in the post‐vaccination samples in 8 of 10 or 8 of 10 patients, respectively. The intensity of CD45RO+ infiltrating cells in the vaccination group was significantly larger than that in the control group. CD8+ T cell infiltration was seen only in the vaccinated group. CONCLUSION: Increased immune responses, at both the circulation and tumor sites in the vaccinated group, support the further development of personalized peptide vaccines for patients with localized prostate cancer. Prostate 67: 933–942, 2007.Keywords
This publication has 25 references indexed in Scilit:
- Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patientsThe Prostate, 2004
- Immunotherapy (APC8015, Provenge®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen‐independent prostate cancer: A phase 2 trialThe Prostate, 2004
- Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular ResponsesClinical Cancer Research, 2004
- Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancerThe Prostate, 2004
- Prostate‐specific antigen‐derived epitopes capable of inducing cellular and humoral responses in HLA‐A24+ prostate cancer patientsThe Prostate, 2003
- Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccinationThe Prostate, 2003
- Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV‐PSA) in patients with metastatic androgen‐independent prostate cancerThe Prostate, 2002
- CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA resultsUrology, 1999
- Tissue microarrays for high-throughput molecular profiling of tumor specimensNature Medicine, 1998
- Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate CancerJournal of Urology, 1995